Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Pregene Out-Licenses India Rights for its CAR-T Therapy to Dr. Reddy's

publication date: May 13, 2021

Shenzhen Pregene Biopharma out-licensed Indian rights for its anti-BCMA CAR-T cell therapy to Dr. Reddy's Labs. Dr. Reddy's will make $5 million in upfront and milestone payments for the first indication of the therapy and $7.5 million for any additional indications. It will also pay double-digit royalties up to $150 million. Dr. Reddy's will be responsible for all development costs in India. In a China investigator-led trial, PRG1801 showed positive signs of efficacy and safety in 34 patients with relapsed/refractory multiple myeloma. More details....

Stock Symbol: (BSE: 500124)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital